The global NIPT market was valued at USD 0.22 billion in 2012 and is expected to grow at a CAGR of 37.6% from 2013 to 2019, to reach an estimated value of USD 3.62 billion in 2019.
The
market for non-invasive prenatal testing is evolving rapidly due the
advantages it offers over the conventional prenatal screening and
diagnostic methods such as maternal serum screening, nuchal translucency
(NT) scan, amniocentesis and chorionic villus sampling (CVS). These
advantages include safety, accuracy, and no risk of miscarriage. An NIPT
is a non-invasive genetic screening test for the common chromosomal
abnormalities (trisomy 21, trisomy 18, trisomy 13, monosomy X, etc.)
observed in the fetuses of high risk pregnant women (above the age of 35
years). Owing to its ability to detect the presence of chromosomal
abnormalities in fetuses of pregnant women as early as 9 to 10 weeks of
gestation, the market for non-invasive prenatal testing is witnessing a
rapid increase in demand from all parts of the world.
MaterniT21
PLUS, verifi, Harmony, Panorama, NIFTY, PrenaTest and BambniTest are
the commercially available NIPTs in the market which are based on the
direct analysis of cell-free fetal DNA in the maternal blood. In 2012,
MaterniT21 (a proprietary product of Sequenom, Inc.) accounted for the
largest share (36.6%) of the global NIPT market in terms of revenue,
owing to the fact that it was the first mover in the market place.
During the forecast period 2013 to 2019, it is likely to lose some of
its share due to increasing market penetration by other aforementioned
NIPTs such as Panorama and verifi.
High
incidence rate of babies born with certain type of chromosomal
abnormalities, growing trend of child bearing at advanced maternal age
and enhanced popularity of NIPT among gynecologists and high risk
pregnant women are some of the major factors anticipated to drive growth
of the NIPT market during the forecast period. Some of the most
commonly detected chromosomal aneuploidies include Down syndrome,
Edwards syndrome, Patau syndrome and monosomy X. On the other hand,
ethical and regulatory hurdles are expected to pose significant
challenges before the NIPT market to grow. Various professional
committees across the world believe that the implementation of NIPT and
the subsequent rise in uptake of prenatal testing is likely to increase
the incidence of abortions. Therefore, professional groups such as The
American College of Obstetricians and Gynecologists (ACOG),
International Society for Prenatal Diagnosis and The Japan Society of
Obstetrics and Gynecology have set up guidelines that limit the use of
non-invasive prenatal testing only to pregnant women at high risk of
chromosomal aneuploidies.
Geographically, North America was the largest regional market in 2012 with a market share of 64.5% of the total revenue generated globally, followed by Europe.
Almost every company operating in this market is adopting the same
business model of marketing their tests via alliances with hospitals,
diagnostic laboratories and physician offices. The increasing
penetration by test developers in European, Asia-Pacific and Middle-East
countries indicates promising growth in the near future in these
markets. Sequenom, Inc., Verinata Health, Inc. (now a part of Illumina,
Inc.), Ariosa Diagnostics, Natera, Inc., BGI Health, LifeCodexx and
Berry Genomics are the companies engaged in providing non-invasive
prenatal tests worldwide.
Related & Recently Published Reports by Transparency Market Research
The global non-invasive prenatal testing market is segmented as follows:
Non-Invasive Prenatal Testing Market, by Test
- MaterniT21 PLUS
- verifi
- Harmony
- Panorama
- NIFTY
- PrenaTest
- BambniTest
Non-Invasive Prenatal Testing Market, by Geography
- North America
- Europe
- Asia-Pacific
- Rest of the World (RoW)
About Us
Transparency
Market Research is a global market intelligence company, providing
global business information reports and services. Our exclusive blend of
quantitative forecasting and trends analysis provides forward-looking
insight for thousands of decision makers. We are privileged with highly
experienced team of Analysts, Researchers, and Consultants, who use
proprietary data sources and various tools and techniques to gather, and
analyze information.
Our
data repository is continuously updated and revised by a team of
research experts, so that it always reflects the latest trends and
information. With a broad research and analysis capability, Transparency
Market Research employs rigorous primary and secondary research
techniques in developing distinctive data sets and research material for
business reports.
Contact
Sheela AK
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
0 comments:
Post a Comment
Note: only a member of this blog may post a comment.